Singapore markets closed

JNJ Jan 2025 230.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.08000.0000 (0.00%)
As of 02:15PM EDT. Market open.
Full screen
Previous close0.0800
Open0.0800
Bid0.0100
Ask1.0600
Strike230.00
Expiry date2025-01-17
Day's range0.0800 - 0.1000
Contract rangeN/A
Volume4
Open interest499
  • PR Newswire

    Sarepta Therapeutics Set to Join S&P MidCap 400

    Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

  • Benzinga

    Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial

    Wednesday, Johnson & Johnson (NYSE:JNJ) announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. Seltorexant is an investigational first-in-class selective antagonist of the human orexin-2 receptor being studied for the adjunctive treatment of MDD with insomnia symptoms. Also Read: Johnson & Johnso

  • Zacks

    Are You Looking for a High-Growth Dividend Stock?

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.